$239 Million is the total value of FRAZIER MANAGEMENT LLC's 7 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GKOS | New | GLAUKOS CORP | $64,277,000 | – | 2,603,362 | +100.0% | 26.88% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $51,627,000 | – | 1,877,332 | +100.0% | 21.59% | – |
| DNAI | New | PRONAI THERAPEUTICS INC | $32,880,000 | – | 2,186,195 | +100.0% | 13.75% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $28,307,000 | – | 2,918,291 | +100.0% | 11.84% | – |
| TBRA | New | TOBIRA THERAPEUTICS INC | $26,819,000 | – | 2,668,570 | +100.0% | 11.21% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $22,518,000 | – | 1,312,258 | +100.0% | 9.42% | – |
| RXDX | New | IGNYTA INC | $12,735,000 | – | 950,366 | +100.0% | 5.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.